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Recent studies from our laboratories (1,  2)  and others  (3,  4)  have confirmed that 
interleukin 2  (IL-2; 1 formerly referred to as T  cell growth factor, or TCGF) purified 
from either mouse, rat, or human lymphocyte conditioned medium retains biologic 
activity in several in vitro murine lymphocyte response assays.  For example, isoelec- 
trically pure IL-2: (a) stimulates the long-term in vitro proliferation of antigen-specific 
effector T  cells; (b) enhances thymocyte mitogenesis; and (c)  induces cytotoxic T  cell 
(CTL) reactivity and plaque-forming cell responses in cultures of nude mouse spleen 
cells (1, 2). Because current preparative purification protocols require fractionation of 
several liters of conventionally prepared conditioned medium to generate submicro- 
gram quantities of IL-2, we have initiated several studies aimed at identifying more 
potent sources of IL-2. After screening >40 malignant murine T  cell lines, we recently 
identified, adapted to in vitro culture, and cloned a  murine T  cell lymphoma that, 
upon T  cell  mitogen stimulation, produces  1,000-10,000 times the  amount of IL-2 
generated  by  similarly activated  mouse  or  rat  spleen  cells,  z  Murine  lymphoma- 
generated IL-2 was found to be biochemically indistinguishable from IL-2 produced 
by ligand-stimulated normal mouse splenocytes.  3 
Based  on  these  results  we  undertook  a  similar screening of several  established 
human leukemic T  and B cell lines for constitutive and lectin-induced  IL-2 production. 
In  this  communication we  report  that  one  such  leukemic T  cell  line  (designated 
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Jurkat-FHCRC)  can  be stimulated by phytohemagglutinin  (PHA)  or concanavatin 
A  (Con  A)  to  produce between  100  and  300  times  the amount  of human  IL-2/ml 
normally generated by lectin-stimulated human peripheral blood lymphocytes (PBL) 
or spleen cells. Because Jurkat-FHCRC-derived IL-2 retained the capacity to promote 
the in vitro proliferation of antigen-activated human  and mouse effector T  cells, we 
feel that such a  line will prove to be a  valuable reagent for investigators interested in 
growing clonal human T  cells with various antigen and effector specificities. Further- 
more, Jurkat-FHCRC  cells will provide a much needed source of concentrated human 
IL-2 conditioned medium to foster further molecular characterization of this lympho- 
cyte regulatory molecule. 
Materials  and  Methods 
Screening of Leukemic  T  and B  Cell Lines for IL-2 Production.  Several  (see  Table I)  in  vitro 
cultured  leukemic T  and  B  cell lines (RPMI-1640  medium,  supplemented with  10%  heat- 
inactivated [56°C for 30 min] fetal calf  serum [FCS], 50 U/ml penicillin, 50/Lg/ml streptomycin, 
and  300/~g/mi  fresh h-glutamine) were tested for both constitutive and  lectin-induced IL-2 
production. Cell lines designated SKI were obtained either from Dr.  Roland Mertelsmann, 
Laboratory of Developmental Hematopoiesis, or Dr.  Peter Ralph, both  from  the Memorial 
Sloan-Kettering Cancer Center, New York. Cell lines designated FHCRC were obtained from 
Dr. John Hansen, Histocompatibility  Laboratory, Puget Sound Blood Center, Fred Hutchinson 
Cancer  Research  Center,  Seattle,  Wash.  (5).  After  harvest  from  exponential  proliferative 
culture, cell line samples (2 ×  106 cells/ml) were resuspended in Click's medium (supplemented 
with  10%  FCS,  25  mM  Hepes  Buffer,  16  mM  NaHCO3,  50  U/ml  penicillin,  50  ffg/ml 
streptomycin, and 300 pg/ml fresh h-glutamine) and seeded in 100-/xl aliquots in replicate flat- 
bottomed  microplate wells  (3596;  Costar,  Data  Packaging,  Cambridge,  Mass.).  Triplicate 
microwell cultures were then stimulated by a 100-/xl addition of either (a) tissue culture medium; 
(b) Con A (20/xg/ml; Miles Biochemicals Inc., Elkhart, Ind.; (c) PHA (PHA-M; 2% by volume; 
Grand  Island Biological Co.,  Grand  Island, N.  Y.);  or (d)  pokeweed mitogen  (PKW;  1/50 
dilution; Grand Island Biological Co.). After the time periods indicated (Results), supernate 
samples  from  triplicate cultures  were  pooled  and  assayed  for  IL-2  activity in  a  standard 
microassay as detailed below. Optimal mitogen dose, harvest time and cell concentration for 
Jurkat-FHCRC-mediated IL-2 production was determined in separate experiments conducted 
either in 200-~1 microwell cultures as detailed above or in 5-ml vol in tissue culture flasks (3013; 
Falcon Labware, Div. Becton, Dickinson & Co., Oxnard, Calif.). All IL-2 production cultures 
were conducted at 37°C in a humidified atmosphere of 5% CO2 and air. 
1L-2  Microassay.  IL-2  activity was  determined  using  a  standard  TCGF  microassay  (6) 
monitoring the IL-2-dependent cellular proliferation of a mouse cytotoxic T  cell line (CTLL) 
(7).  Briefly, 3,000  CTLL cells were seeded in replicate 200-#1 vol  (in 96-well fiat-bottomed 
microtiter plates) in the presence of a  log2 dilution series of a  given IL-2-containing sample. 
After 24 h of culture (at 37°C in a  humidified atmosphere at 5% and air) microwell cultures 
were pulsed for 4 h  with 0.5 p.Ci of tritiated thymidine ([aH]Tdr; 20 mCi/mM sp act, New 
England Nuclear, Boston, Mass.) after which time the cultures were harvested onto glass fiber 
filter strips with the aid a  multiple automated sample harvester (Microbiological Associates). 
[3H]Tdr incorporation was determined by liquid scintillation counting. Using these methods, 
only CTLL cells cultured in the presence of IL-2 incorporated [3H]Tdr in a  dose-dependent 
manner. CTLL cells cultured in the absence of IL-2 incorporated only scintiilant control levels 
of ['~H]Tdr and were >95% trypan-blue positive after 24 h of IL-2 deprivation. Units of IL-2 
activity were  determined  by  probit  analysis of [3H]Tdr  incorporation data  (6).  A  1 U/ml 
standard  was  defined as  the  amount  of IL-2 activity present  in  48  tissue culture  medium 
conditioned by the Con A (5/~g/ml) stimulation of normal rat spleen cells (10  s cells/ml). Assay 
of 1 U/ml  standard  routinely stimulated  10,000  cpm  of CTLL  [3H]Tdr incorporation at  a 
dilution of 1:2. 
To confirm that the IL-2 activity produced by PHA-stimulated Jurkat-FHCRC cells would 
support  the  sustained  in  vitro  proliferation of human  activated  T  cells,  identical  TCGF STEVEN GILLIS AND JAMES WATSON  1711 
microassays  were  conducted  using  an  IL-2-dependent  human  cytotoxic  T  cell  line  as  the 
indicator cell  (105  cells/ml). This cell line, designated  MLR-FHCRC-1  was developed from 
effector cells harvested from a  10-d mixed lymphocyte reaction and had been in IL-2-dependent 
culture for 4-6 weeks before use in TCGF microassays. 
The amount of IL-2 activity generated by Jurkat-FHCRC cells was compared to that present 
in several other sources of conditioned medium. Conditioned media were prepared  by the T 
cell mitogen stimulation of normal murine or rat spleen cells. IL-2-containing supernates were 
also generated from single donor human PBL stimulated with (a) PHA; (b) PHA and allogeneic 
cells  from  an  in  vitro  cultured  B  lymphoblastoid  cell  line  (Ar-77,  obtained  from  Dr.  R. 
Mertelsmann); or (c) neuraminidase and galactose-oxidase (NaGO). Additional IL-2-eontaining 
supernates  were produced  by the  1%  PHA stimulation  of either normal  human  spleen cells 
(obtained  from  Dr.  Michael  Bean,  Virginia Mason  Research  Center,  Seattle, Wash.)  or the 
mouse lymphoma LBRM-33. Methods for production of all of the above IL-2-eontaining tissue 
culture media have been detailed elsewhere (6-9). 2, a 
Results 
Screening of Human  T and B  Leukemia Cell Lines for IL-2 Production.  Table I  details 
constitutive  and  lectin-induced  IL-2  production  by  48-h  cultures  of  16  cell  lines. 
Where possible, identical cell lines were obtained from two different sources in the 
event that upon subsequent long-term culture, one derivative might have expressed 
a capacity to produce IL-2. Of the lines tested, only one, the T  cell leukemia Jurkat- 
TABLE  I 
Screening of Cultured Human  T and B Cell Leukemias for IL-2 Production 
IL-2 activity present  in 48-h supernate after activation 
with 
Medium*  Con-A~:  PHA§  PKWII 
Ulrnl 
T cell leukemias 
CEM-SKI  0.0  0.0  0.0  0.0 
CEM-FHCRC  0.0  0.0  0.0  0.0 
8402-FHCRC  0.0  0.0  0.0  0.0 
HSB2-SKI  0.0  0.0  0.0  0.0 
HSB2-FHCRC  0.0  0.0  0.0  0.0 
Molt-4-SKI  0.0  0.0  0.0  0.0 
Molt-4-FHCRC  0.0  0.0  0.0  0.0 
Ke37-FHCRC  0.0  0.0  0.0  0.0 
T-45-SKI  0.0  0.0  0.0  0.0 
R-2-SKI  0.0  0.0  0.0  0.0 
Peer-SKI  0.0  0.0  0.0  0.0 
HPB-ALL-SKI  0.0  0.0  0.0  0.0 
Jurkat-FHCRC  0.0  93.7  225.0  52.1 
B cell leukemias 
Daudi-SKI  0.0  0.0  0.0  0.0 
Nalm- 1-SKI  0.0  0.0  0.0  0.0 
8866-FHCRC  0.0  0.0  0.0  0.0 
AR-77-SKI  0.0  0.0  0.0  0.0 
* RPMI-1640,  10% FCS. 
:~ 10/tg/ml. 
§ 1.0% by volume. 
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FHCRC,  produced significant quantities of IL-2 after mitogen sensitization. In fact, 
1% PHA stimulation of  Jurkat-FHCRC  cells resulted in the elaboration of conditioned 
media that contained 225 times the amount of IL-2 present in a  standard rat spleen 
cell preparation of Con A conditioned medium (Materials and Methods). None of the 
cells tested demonstrated  a  capacity for constitutive  IL-2 production.  It  should  be 
stressed  that  the  IL-2  production  data  detailed  in  Table  I  were  not  significantly 
different  when  supernates  were  harvested  from  24-  or  72-h  medium  and  lectin- 
stimulated  cultures  (data  not  shown).  Therefore,  it  is  probable  that  the  cell  lines 
identified as negative for IL-2 production (using the concentrations oflectin indicated) 
do not yield negative values because of an alteration in production kinetics. 
The  amount  of IL-2 activity produced  by  PHA-stimulated Jurkat-FHCRC  cells 
was quite significant especially in comparison to more conventional sources of human 
conditioned medium. As demonstrated in Table II, only PHA-stimulated LBRM-33 
cells (a radiation-induced splenic lymphoma from the B 10.BR mouse) produced more 
IL-2 activity than Jurkat-FHCRC  leukemia cells.  2' a Clearly, the Jurkat-FHCRC  cells 
were the reagent of choice for production of highest titer IL-2 from  human  sources. 
The supernates generated by  1% PHA-stimulated Jurkat-FHCRC  cells contained  10 
times  the  amount  of  IL-2  produced  by  the  next  most  successful  method  (dual 
stimulation of single donor  peripheral blood  leukocytes by  PHA  and  a  B  lympho- 
blastoid cell line). It is of interest to note that NaGO stimulation of human  PBL lead 
to the generation of IL-2-containing conditioned medium. This treatment was origi- 
nally described by Novogrodsky et  al.  (11)  as a  method  for initiating human  T  cell 
TABLE  II 
Relative Capacity of Rat, Mouse, and Human Lymphocyte Populations to Produce IL-2 
Cell con- 
Lymphocyte source  Mitogen  centration* 
IL-2 (TCGF) activity in filtered 
medium 













Human  T  cell  leukemia 
Jurkat-FHCRC 
U/mt 
Con-A (1.25/tg/ml)  106/ml  O.10  0.35 
Con-A (2.5 gg/ml)  107/ml  1.60  0.75 
Con-A (5 gg/ml)  106/ml  0.68  1.0 (standard) 
Con-A (5 gg/ml)  107/illl  13.60  7.20 
PHA VT,  10"/ml  2.30  4..30 
B-LCL:~ (Daudi or AR-77  106/ml  0.63  1.20 
2 X 10s-5 X 10'~/ml live 
or irradiated) 
B-LCL +  1.0% PHA  106/ml  8.60  10.70 
NaGO{}  106/ml  3.60  0.73 
1~7,: PHA  107/ml  25.00  12.60 
I~ PHA  106/ml  535.00  520,00 
1'7~. PHA  106/ml  206.00  185.00 
* 50-ml vol in 250-mm  2 flasks lying flat in a humidified atmosphere of 5% CO2. 
:~ B lymphoblastoid cell line. 
§ NaGO treatment (8). STEVEN GILLIS AND JAMES WATSON  1713 
proliferation, and provided an excellent means of producing low titer, but mitogen- 
free, human IL-2. 
Because the experiments described in both Tables I and II monitored IL-2 activity 
on the basis of its capacity to sustain the in vitro proliferation of murine activated T 
cells, it was not necessarily clear that PHA-stimulated Jurkat-FHCRC cells produced 
significant amounts of human IL-2 activity. To approach this problem, both Jurkat- 
FHCRC and LBRM-33 conditioned medium were tested for their capacity to induce 
proliferation of both murine CTLL and human MLR reactive T  cell lines harvested 
from IL-2 dependent cultures. Results of these experiments are displayed in Fig.  1 in 
terms of [aH]Tdr incorporation observed in cultures that contained various concen- 
trations of conditioned medium. Jurkat-FHCRC-derived IL-2 activity was capable of 
sustaining the in vitro proliferation of both murine and human CTLL. LBRM-33- 
generated conditioned medium proved effective only when tested on murine CTLL. 
Tissue culture medium that contained 1% PHA was incapable of inducing prolifera- 
tion of either mouse or human activated T  cells. These data were consistent with our 
previous studies detailing the species specificity of IL-2 (6) and confirmed that Jurkat- 
FHCRC conditioned medium was an excellent source Of human IL-2 activity. 
Jurkat-FHCRC IL-2 Production Kinetics and Mitogen Dose Responses.  To determine the 
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Fro.  1.  [aH]Tdr incorporation  (4-hour pulse) by murine (A) and human (B)  CTLL cells after a 
24-h culture in a log2 dilution series of medium conditioned by 1% PHA-stimulated Jurkat-FHCRC 
(&)  or LBRM-3 cells (O).  Response is also indicated after culture in  1% PHA (0).  Maximal[aH]- 
Tdr  incorporation  witnessed  by  murine  and  human  CTLL  cells  was  10,984  and  6,530  cpm, 
respectively. LBRM-3-derived supernate contained 936 U/ml IL-2, whereas Jurkat-FHCRC-gen- 
crated cbnditioned medium contained 225 U/ml IL-2 activity. 1714  INTERLEUKIN 2-PRODUCING HUMAN LEUKEMIA T  CELL LINE 
vested from in  vitro culture  and  seeded in  replicate  flat-bottomed microplate wells 
(106 cells/ml) in the presence of 1% PHA. After 2, 4, 6, 8,  10,  12, 24,  48 h of cuhure, 
supernates were harvested  and assayed for IL-2 activity on murine CTLL cells.  As 
shown in Fig.  2,  detectable IL-2 activity was first observed between 5 and  7 h  after 
PHA stimulation.  Peak levels of IL-2 were present  in  16-24  h  cultured  supernates 
(100-250  U/ml)  and these titers diminished only slightly during a  subsequent  24-h 
culture.  As  such,  Jurkat-FHCRC  IL-2  production  kinetics  were  similar  to  those 
previously detailed for cultures of lectin-stimulated rat, mouse and human mononu- 
clear leukocytes where measurable IL-2 activity was detected within 6 h after mitogen 
stimulation  (6).  However, in addition  to the magnitude of the factor produced,  the 
kinetics of IL-2 production from Jurkat-FHCRC ceils were somewhat different from 
that  observed  from  normal  cells  in  that  the  amount  of IL-2  present  in  post-peak 
cultures did not significantly decline over time. This is routinely observed in normal 
spleen and/or PBL IL-2 production as activated T  cells absorb and use the IL-2 to 
foster their own proliferation  (10).  In fact, Jurkat-FHCRC cells in  IL-2 production 
cultures were >95% trypan-blue positive after a 48-h stimulation with  I% PHA (data 
not shown). At present, it is difficult to distinguish whether Jurkat-FHCRC ceils die 
as  a  result  of IL-2  production  or  whether  IL-2  is  released  as  a  result  of mitogen 
toxicity.  Attempts to  isolate active IL-2 from supernates of non-stimulated Jurkat- 
FHCRC cells (via sonication or heat treatment) have been unsuccessful. Therefore, it 
is questionable  whether IL-2 is preformed in  the cytoplasm of Jurkat-FHCRC cells 
and  is  released  into  the  medium  after mitogen  sensitization.  The observation  that 
increasing concentrations of IL-2 are found over a  16-h  time period in supernates of 
stimulated  Jurkat-FHCRC  cells  (Fig.  2)  also  argues  against  the  hypothesis  that 
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Fro.  2.  Jurkat-FHCRC IL-2  production kinetics. Supernate IL-2 activity (O) monitored over time 
after stimulation of Jurkat-FHCRC cells (106/ml) with 1% PHA. STEVEN  GILLIS AND JAMES WATSON  1715 
mitogen  activation  simply stimulates  cell  death  and  concommitant  release of pre- 
formed IL-2. 
Experiments  similar  to  those  displayed  in  Fig.  2  were  conducted  to  determine 
optimal Jurkat-FHCRC  cell concentration for IL-2 production. Based on the produc- 
tion kinetics, supernates were harvested from cultures that contained various concen- 
trations  of Jurkat-FHCRC  cells  (ranging  from  106  to  107  cells/ml)  24  h  after 
stimulation with  1%  PHA  and  assayed for IL-2 activity on  murine CTLL  cells. As 
shown in Table III, optimal cell concentration for peak Jurkat-FHCRC  IL-2 produc- 
tion  was  ~106  cells/ml.  Identical  experiments  were  also  conducted  to  determine 
optimal mitogen concentration for Jurkat-FHCRC  IL-2 production. Cells were plated 
in replicate microwell cultures (10  ~ cells/ml) and stimulated with a  range of concen- 
trations of PHA  (0.1-10%)  and  Con  A  (1.25-100/.tg/ml).  As detailed in Table IV, 
peak IL-2 production (>350 U/ml) was observed in either 1% PHA- or 20 ~g/ml Con 
A-stimulated cultures. 
Effect of Phorbol Myristate  Acetate  (PMA) on Jurkat-FHCRC IL-2 Production.  Several 
groups  have  investigated the effects of macrophages on  IL-2 production  by normal 
TABLE III 
Jurkat-FHCRC-derived IL-2 Production: Optimal Cell Concentration 
Jurkat-FHCRC cell concentration  IL-2 activity present in 24-h supernate 
after 1% PHA stimulation 
U/ml 
107/ml  103 
5 ×  106/ml  151 
2 ×  106/ml  193 
106/ml  225 
5 X 10~/ml  178 
2 X 10'~/ml  53 
105/ml  26 
5 X 104/ml  10 
TABLE IV 
Jurkat-FHCRC-derived IL-2 Production: Mitogen Dose Responses 
Mitogen  Concentration  IL-2 activity* 
U/ml 
PHA  10%  101 
PHA  5%  135 
PHA  2%  171 
PHA  I%  252 
PHA  0.5¢7~  234 
PHA  0.2%  117 
PHA  0.1%  39 
Con A  100/.tg/m[  124 
Con A  50/~g/ml  17 I 
Con A  20 #g/ml  207 
Con A  10 p.g/ml  121 
Con A  5 ,ttg/ml  14 
Con A  2/xg/ml  11 
Con A  1  ,ttg/ml  8 
* 24-h supernate assayed on routine CTLL ceils. 1716  INTERLEUKIN  2-PRODUCING  HUMAN  LEUKEMIA  T  CELL  LINE 
murine spleen cells.  These studies  indicated  that  either supernates  harvested from 
macrophage tumor cells (11) or, more recently, purified interleukin 1 (IL-1; previously 
referred to as lymphocyte-activating factor [or LAF])  could restore the capacity of 
adherent-cell-depleted murine T  cells to produce IL-2 after mitogen stimulation (12, 
3).  Based  on  the  results  of  Farrar  and  Fuller-Bonar  (14)  who  found  that  the 
unsaturated fatty acid derivative PMA provided a similar macrophage replacement 
for T  cell IL-2 production, we also investigated the effects of PMA on LBRM-33 (an 
IL-2-producing  murine  T  cell  lymphoma).  We  found  that  addition  of PMA  to 
suboptimally (0.1% PHA) stimulated LBRM-3 cells restored IL-2 production in such 
cultures to a level equal to that generated by cells stimulated with optimal (1% PHA) 
amounts of mitogen.  2 
Based on these results, we were curious to determine if PMA stimulation would 
affect  Jurkat-FHCRC-derived  IL2  production.  We  therefore  stimulated  Jurkat- 
FHCRC cells with PMA (10 ng/ml), as well as with  1% and 0.1% PHA either alone 
or in concert with PMA. After 24 h of culture, supernates were harvested and tested 
for IL-2 activity. The results of three replicate experiments are shown in Table V. In 
contrast  to  our  previous  observations  with  LBRM  33  cells,  PMA  stimulation  of 
Jurkat-FHCRC cells in the absence of mitogen lead to considerable IL-2 production 
(65 U/ml). Addition of PMA to optimally stimulated (1% PHA) Jurkat-FHCRC ceils 
served to boost IL-2 production titer even higher (>400 U/ml)  than that observed 
when Jurkat-FHCRC were optimally stimulated with PHA alone. Finally, as we had 
observed with murine IL-2 producer lymphoma cells,  2 addition of PMA to subopti- 
mally stimulated Jurkat-FHCRC  cells restored IL-2 production to levels observed 
when peak concentrations of mitogen were used (--200 U/ml). 
Discussion 
The  experiments  detailed  in  this  communication  demonstrate  the  capacity  of 
Jurkat-FHCRC leukemic T cells to produce human IL-2. Jurkat-FHCRC-derived IL- 
2 has T  cell proliferation-inducing activity as tested using both murine and human 
cultured  T  cell  lines.  Jurkat-FHCRC  cells  were  observed  to  produce  IL-2  upon 
stimulation with appropriate concentrations of T  cell mitogens; however, the quan- 
tities of factor generated far exceeded those routinely obtained from more conventional 
TABL~ V 
Effect of PMA on Jurkat-FHCRC Cell Line IL-2 Production 
Jurkat-FHCRC  cells stimulated with* 
PMA (10 ng/ 
1% PHA  0.1% PHA  ml) 
IL-2 activity present in 
24-h conditioned 
medium:~ 
-§  -  -  o.o  ±  o.o 
--  --  +  65.0 "+  17.0 
-  +  -  39.O _  3.6 
+  -  -  210.0 ±  16 
-  +  +  178 +_ 42 
+  -  +  462.0 +  76 
*  l0  s cells/ml in RPMI-1640  10%  FCS. 
:~ Mean  --I-  1  SD  IL-2  (U/ml)  activity present  in  supernates  harvested from 
three separate experiments. 
§ --, not present in culture; +, denotes present in culture. STEVEN GILLIS AND JAMES WATSON  1717 
modes of human IL-2 production. Peak titers of I L-2 (150-350 U/ml) were present in 
16- to 24-h cultured supernates of either  1% PHA- or 20-/xg/ml Con A  stimulated 
Jurkat-FHCRC cells (106 cells/ml). This compares with titers of ~ 10-15 U/ml of IL- 
2 activity produced either by (a) PHA-stimulated spleen or (b) PHA and allogeneic B 
lymphoblastoid cell line stimulation of normal human  PBL. Still higher titer IL-2- 
containing supernates (400 U/ml) were produced by addition of PMA (10 ng/ml) to 
1% PHA-stimulated Jurkat-FHCRC cultures. 
In  addition  to providing a  new  source for the  isolation  and  characterization of 
human IL-2, the capacity of a continuously cultured T  cell leukemia line to produce 
IL-2 may provide additional insight  into normal  IL-2 production and the role that 
abberrant IL-2 regulation might play in the etiology of human leukemia. For example, 
the observation that Jurkat-FHCRC  lymphoma cells die after release of IL-2, may 
have some relationship to the normal condition. No evidence has been presented to 
date either in the mouse or human system to suggest that after ligand activation, the 
IL-2-producing T  cell responds to IL-2 or even survives. If IL-2 producer cells were 
capable  of responding  to  IL-2,  one  would  expect  that  after  mitogen  or  antigen 
sensitization,  these  cells would  continue to  proliferate by their own accord;  if not 
indefinitely, at least to the point where they would represent a substantial proportion 
of the cells surviving ligand stimulation. Clearly, this is not the case. Activated T  cells 
have been grown in culture only by the continual addition of IL-2. In all cases, such 
cell  lines  have been  shown  to mediate effector T  cell function  and  have not  been 
found to demonstrate capacity for IL-2 production (7, 9,  15). The notion that  I1-2- 
producing cells die upon  factor release is also supported  from our previous studies 
conducted on an IL-2-producing murine T  cell lymphoma. In these experiments, we 
found that  the high-titer IL-2-producing LBRM 33 cell line dies after lectin stimu- 
lation and IL-2 release.  2 
The hypothesis that T  cell leukemia may represent a population of IL-2 producer 
cells  that  responds  to  its  own  factor  is  an  intriguing  one.  One  might,  therefore, 
envision a  leukemic T  cell as a  cell with both IL-2 production and response (surface 
receptor) capacities.  Such autostimulatory roles for factor production and use have 
recently been invoked in the relationship of sarcoma growth factor to the sustained in 
vitro proliferation of sarcoma virus-transformed ceils  (16).  Similar autostimulatory 
viral  antigen  presentation  has  been  suggested  as  a  possible  explanation  for  the 
proliferation observed in virus-induced murine thymomas (17). Given the knowledge 
that  IL-2  is  responsible  for  antigen-initiated  T  cell  replication  (2),  the  potential 
involvement  of IL-2  in  the  uncontrolled  replication  of leukemic  T  cells  may  be 
considerable. For example, in screening 49 samples of adult human leukemic blasts, 
we observed that  >95%  of those patients  whose malignant  cells tested positive for 
cytosol terminal deoxynucleotidyl transferase (TDT) produced significant amounts of 
IL-2 (>20 U/ml)  upon mitogen stimulation  (18). Furthermore, IL-2 production by 
TDT-positive leukemic blasts was accompanied by extremely poor mitogen-induced 
T  cell proliferation (18).  One possible (among several) hypothesis for such a  finding 
might  be that  leukemic T  cell IL-2 receptors were previously saturated  by cellular 
factor production. Therefore, upon increased synthesis of IL-2 one would expect little, 
if any,  effect  on  already  active  replicatory  processes.  Alternatively,  poor  T  cell 
proliferation in the face of high IL-2 production might suggest a lack of IL-2 receptors 
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(cessation of proliferation) on human leukemia cell replication. This possibility was 
further suggested by the observation that addition of exogenous purified human IL- 
2 to TDT-positive leukemic cells resulted in a significant diminution of leukemic cell 
proliferation as monitored by [3H]Tdr incorporation in 24- to 72-h cultures. Finally, 
it is possible to interpret the above findings simply by cell death upon IL-2 release as 
we have noted for both Jurkat-FHCRC and LBRM-33 T  cell malignancies. 
In addition to serving as a useful model system for studying the involvement of IL- 
2  production and  use in human  leukemia, Jurkat-FHCRC  cells will be a  valuable 
reagent in the generation of large amounts of human IL-2 for further purification and 
molecular characterization. In this regard, it is fortunate that Jurkat-FHCRC  cells 
produce large quantities of IL-2 upon mitogen stimulation. Additionally, the obser- 
vation that PMA (a small molecular-weight and removable stimulant) triggers Jurkat- 
FHCRC IL-2 production, suggests that PMA stimulation may prove even more useful 
in allowing for production of large quantities of mitogen-free human IL-2-containing 
supernates.  Eventually such stimulation protocols might prove useful for large scale 
production of biosynthetically radiolabeled human  IL-2.  Radioactive human  IL-2 
would be most useful not only for detailed analysis of factor function but, in addition, 
as a screening reagent for generation of monoclonal anti-IL-2 antibodies. 
Summary 
To isolate a stable tumor cell line capable of producing human interleukin 2 (IL-2; 
formerly referred to as T  cell growth factor), 16 human T  and B leukemia cell lines 
were screened for constitutive and  mitogen-stimulated  IL-2 production.  We found 
that the T  cell leukemia line designated Jurkat-FHCRC produced >200 U/ml of IL- 
2 activity after a  24-h stimulation with T  cell mitogens. Peak mitogen-induced IL-2 
activity was  found in supernates harvested from 24-h Jurkat-FHCRC  cell cultures 
stimulated with either 1% phytohemagglutinin or 20 #g/ml concanavalin A. Addition 
of the fatty acid derivative phorbol myristate acetate to mitogen-stimulated cultures 
increased Jurkat-FHCRC IL-2 production to concentrations >400 U/ml. IL-2 activity 
observed in such cases represented between  100-300 times that produced in conven- 
tional cultures of mitogen- or alloantigen-stimulated normal human peripheral blood 
or splenic lymphocytes. Jurkat-FHCRC-derived conditioned medium demonstrated 
equal  capacity to promote the sustained  in  vitro proliferation of either murine or 
human activated T cell lines confirming the ability of  Jurkat-FHCRC cells to produce 
human  IL-2.  These studies  identify a  new  source of human  IL-2  and  establish  a 
valuable  reagent  for  the  isolation  and  further  molecular  characterization  of this 
immunoregulatory molecule. 
We  thank  Doctors  Roland  Mertelsmann,  Peter  Ralph,  and John  Hansen  for generously 
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